Skip to main content
letter
. 2015 Feb;100(2):e63–e67. doi: 10.3324/haematol.2014.112557

Figure 1.

Figure 1.

Trial design. aProgression of disease was independently adjudicated in real time. bHiDEX was chosen as comparator because at the time of trial design it was the standard salvage therapy for heavily pre-treated patients. D: days; HiDEX: high-dose dexamethasone; LoDEX: low-dose dexamethasone; OS: overall survival; PD: progressive disease; POM: pomalidomide; SPM: second primary malignancy.